Morphic Holding, Inc. (NASDAQ:MORF – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $59.75.
A number of research analysts recently weighed in on MORF shares. Leerink Partnrs restated an “outperform” rating on shares of Morphic in a research note on Monday, October 16th. Citigroup assumed coverage on shares of Morphic in a report on Friday, December 8th. They set a “buy” rating and a $46.00 price target on the stock.
Insider Transactions at Morphic
Hedge Funds Weigh In On Morphic
Several large investors have recently made changes to their positions in MORF. Bank of New York Mellon Corp increased its position in shares of Morphic by 0.3% in the 1st quarter. Bank of New York Mellon Corp now owns 88,123 shares of the company’s stock valued at $3,317,000 after purchasing an additional 232 shares during the last quarter. Metropolitan Life Insurance Co NY boosted its holdings in shares of Morphic by 20.5% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 1,663 shares of the company’s stock valued at $95,000 after buying an additional 283 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Morphic by 3.8% in the 4th quarter. Legal & General Group Plc now owns 8,472 shares of the company’s stock valued at $227,000 after buying an additional 309 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Morphic by 63.4% in the 1st quarter. Tower Research Capital LLC TRC now owns 951 shares of the company’s stock valued at $36,000 after buying an additional 369 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Morphic by 28.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,513 shares of the company’s stock valued at $144,000 after buying an additional 557 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.
Morphic Trading Up 1.5 %
NASDAQ:MORF opened at $40.31 on Thursday. Morphic has a 12 month low of $19.34 and a 12 month high of $63.08. The company has a 50 day simple moving average of $29.90 and a two-hundred day simple moving average of $34.11. The company has a market cap of $2.01 billion, a PE ratio of -12.64 and a beta of 1.41.
Morphic Company Profile
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.
- Five stocks we like better than Morphic
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 attractive stocks that insiders are buying
- How to Invest and Trade Chinese Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- What is Insider Trading? What You Can Learn from Insider Trading
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.